Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.

@article{Torre2016SuperiorEA,
  title={Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.},
  author={Ana V de la Torre and Kirenia C. P{\'e}rez and A. M. Rincon Vega and Eduardo R. Santiesteban and Raiza Garcez Ruiz and Leonardo S{\'a}nchez Hern{\'a}ndez and Dayam{\'i} Durrut{\'i} and Carmen Elena Viada and Liset Schery S{\'a}nchez and Mabel Poblete {\'A}lvarez and Yunier Dur{\'a}n and Yoisbel G Moreno and M Lorente Arencibia and Meyl{\'a}n Cepeda and Milagros Domecq and Leticia Su{\'a}rez Cabrera and Jorge D. L{\'o}pez S{\'a}nchez and Jose Joel Hernandez and Ana R Valls and Luis E. Fern{\'a}ndez},
  journal={Breast cancer : basic and clinical research},
  year={2016},
  volume={10},
  pages={
          5-11
        }
}
NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane protein complex of Neisseria meningitidis, has been previously tested in a Phase II trial in patients with metastatic breast cancer (MBC) but emulsified with Montanide ISA 51. An Expanded Access study was carried out in MBC patients aiming to find if a nonemulsive… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

HS Rugo, AJ Chien, SX Franco
  • Breast Cancer Res Treat
  • 2012

Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003

Similar Papers

Loading similar papers…